Skip to main content
Caplight Logo









SemaThera Inc

SemaThera Inc

Private
MontrealHealthcare & Life Scienceshttps://semathera.com

Last Round

Series A

Mar 21, 2018

Total Funding Raised

$2.76M

Company Overview

SemaThera Inc is a biotechnology company that develops novel inhibitors of semaphorin 3A for the prevention and reversal of retinal vascular diseases such as diabetic retinopathy and diabetic macular edema.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyretinal diseasedrug discoveryophthalmologybiologic therapeuticsprotein trapbiotech startupbispecific proteinmacular degenerationVEGFSEMA3Apreclinical developmenttherapeutic licensingdiabetic retinopathybiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Book a demo to explore historical pricing and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Book a demo

For institutional investors. Book with your work email.

SemaThera Inc Comparables

Compare SemaThera Inc with similar companies based on industry and business-model similarity.

SemaThera Inc comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AsclepiX Therapeutics
87%
Memento Medicines
82%
Boehringer Ingelheim
73%
Book a demo to see all comparables

For institutional investors. Book with your work email.

SemaThera Inc Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 21, 2018
SeedJan 11, 2017
Book a demo to see all 2 rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Mike Sapieha

Founder Chief Scientific Officer

Founding Team

Véronique Bougie

Consulting Chief Operating Officer

Executive Team

For institutional investors. Book with your work email.

SemaThera Inc Investors

Notable investors and investment history

SemaThera Inc investors
InvestorRounds
AmorChemSeed
Book a demo to see all investors

For institutional investors. Book with your work email.

SemaThera Inc Filings

Explore SEC and related filing metadata, where available.

SemaThera Inc filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about SemaThera Inc's valuation, stock price, and market status.

Is SemaThera Inc a public or private company?

SemaThera Inc is a private company.

What is the current stock price of SemaThera Inc?

SemaThera Inc is a private company, so its shares have no public market price. Caplight tracks SemaThera Inc's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is SemaThera Inc worth (valuation)?

Valuation information for SemaThera Inc is not publicly available.

Can I buy SemaThera Inc stock?

SemaThera Inc shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was SemaThera Inc's last funding round?

SemaThera Inc's most recent funding round was Series A on March 21, 2018.

Who are the main investors in SemaThera Inc?

Key investors in SemaThera Inc include AmorChem.

Will SemaThera Inc IPO soon?

No public IPO plans have been announced for SemaThera Inc.

How can I track SemaThera Inc secondary market activity?

Caplight tracks bids, offers, and trades in SemaThera Inc's shares on secondary markets.

Firmographic Details

HeadquartersMontreal
Employee Range5
Year Founded2016
Last FundingMar 21, 2018

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?